NeuroVia
Dedicated to halting the progression of severe neurological disorders and improving patient outcomes.
Dedicated to halting the progression of severe neurological disorders and improving patient outcomes.
NeuroVia is a biopharmaceutical and biotechnology startup dedicated to halting the progression of severe neurological disorders and improving patient outcomes. Founded in 2013, the company is committed to addressing unmet medical needs in neurological diseases, with the primary goal of arresting the onset of devastating neurological deficits associated with X-ALD. NeuroVia has received a significant $14.00M Series A investment on 20 July 2017 from notable investors including Novartis Venture Fund, Sanofi Ventures, Enso Ventures, and BioMed Ventures. This substantial funding reflects the confidence of key industry players in the potential of NeuroVia's innovative approach to effectively address the challenges posed by neurological disorders.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $14.00M | 4 |
|
20 Jul 2017 |
No recent news or press coverage available for NeuroVia.
We care about your data, and we'd love to use cookies make your experience better.
